Serotonin mediates beneficial effects of Hypericum perforatum on nicotine withdrawal signs

Phytomedicine

Volumn 14, Issue 10, 2007, Pages 645-651

  Mannucci, C ^a   Pieratti, A ^a   Firenzuoli, F ^c   Caputi, A P ^a,b   Calapai, G ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c SAN GIUSEPPE HOSPITAL   (Italy)

Author keywords

5 HT1A; Hypericum perforatum; Nicotine; Serotonin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; HYPERICUM PERFORATUM EXTRACT; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NICOTINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SODIUM CHLORIDE;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; HYPERICUM PERFORATUM; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTONIN METABOLISM; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; HYPERICUM; MALE; MICE; MOTOR ACTIVITY; NICOTINE; PHYTOTHERAPY; PLANT EXTRACTS; RECEPTORS, SEROTONIN, 5-HT1; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA; HYPERICUM; HYPERICUM PERFORATUM; MUS;

EID: 34548764364     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2007.06.005     Document Type: Article

References (35)

1. Balfour D.J., and Ridley D.L. The effects of nicotine on neural pathways implicated in depression: a factor in nicotine addiction?. Pharmacol. Biochem. Behav. 66 (2000) 79-85
2. Calapai G., Squadrito F., Rizzo A., Marciano M.C., Campo G.M., and Caputi A.P. Multiple action of the coumarine derivative cloricromene and its protective effects on ischemic brain injury. Naunyn Schmiedebergs Arch. Pharmacol. 351 (1995) 209-215
3. Calapai G., Crupi A., Firenzuoli F., Costantino G., Inferrera G., Campo G.M., and Caputi A.P. Effects of Hypericum perforatum on levels of 5_hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalons and brainstem of the rat. J. Pharm. Pharmacol. 51 (1999) 723-728
4. Calapai G., Crupi A., Firenzuoli F., Inferrera G., Gilberto G., Parisi A., De Sarro G., and Caputi A.P. Interleukin-6 involvement in antidepressant action of Hypericum perforatum. Pharmacopsychiatry 34 (2001) S8-S10
5. Calapai G., Crupi A., Firenzuoli F., Inferrera G., Squadrito F., Parisi A., De Sarro G., and Caputi A.P. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum. Pharmacopsychiatry 34 2 (2001) 45-49
6. Carton S., Houezec J., Lagrue G., and Jouvent R. Early emotional disturbances during nicotine patch therapy in subjects with and without a history of depression. J. Affect. Disord. 72 (2002) 195-199
7. Catania M.A., Firenzuoli F., Crupi A., Mannucci C., Caputi A.P., and Calapai G. Hypericum perforatum attenuates nicotine withdrawal syndrome in mice. Psychopharmacology 169 (2003) 186-189
8. Cryan J.F., and Leonard B.E. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Hum. Psychopharmacol. 15 (2000) 113-135
9. De Smet P.A., and Nolen W.A. St. John's wort as an antidepressant. BMJ 313 7052 (1996) 241-242
10. Deutscher Arzneimittel-Codex, 1991. German drug-codex, DAC 1986, 3. Erg. 91. Monographie Johanniskraut. DAC-1986, 3rd Suppl., 1991.
11. Dierker L.C., Avenevoli S., Stolar M., and Merikangas K.R. Smoking and depression: an examination of mechanisms of comorbidity. Am. J. Psychiatry 159 (2002) 947-953
12. Estrada-Camarena E., Fernandez-Guasti A., and Lopez-Rubalcava C. Antidepressant-like effect of different estrogenic compounds in the forced swimming test. Neuropsychopharmacology 28 5 (2003) 830-838
13. A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam. Clin. Pharmacol. 10 (1996) 16-27
14. Hayford E.K., Patten C.A., Rummans T.A., Schroeder D.R., Offord K.P., Croghan I.T., Glover E.D., Sachs D.P., and Hurt R.D. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br. J. Psychiatry 174 (1999) 173-178
15. Isola R., Vogelsberg V., Wemlinger T.A., Neff N.H., and Hadjiconstantinou M. Nicotine abstinence in the mouse. Brain Res. 850 (1999) 189-196
16. Kasper S. Hypericum perforatum - a review of clinical studies. Pharmacopsychiatry 34 Suppl. 1 (2001) S51-S55
17. 1A receptor gene expression in the cerebral cortex and dorsal hippocampus. Eur. J. Neurosci. 13 (2001) 1267-1271
18. Linde K., Ramirez G., Mulrow C.D., Pauls A., Weidenhammer W., and Melchart D. St. John's wort for depression - an overview and meta-analysis of randomised clinical trials. Br. Med. J. 313 (1996) 253-258
19. Markou A., Kosten T.R., and Koob G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsycopharmacology 18 (1998) 135-174
20. Murray C.J., and Lopez A.D. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349 (2001) 1436-1442
21. Olausson P., Engel J.A., and Soderpalm B. Involvement of serotonin in nicotine dependence: processes relevant to positive and negative regulation of drug intake. Pharmacol. Biochem. Behav. 71 (2002) 757-771
22. Peroutka S.J. 5-Hydroxytryptamine receptors. J. Neurochem. 60 (1993) 408-416
23. Phillipp M., Kohnen R., and Hiller K. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 319 (1999) 1534-1538
24. Picciotto M.R. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol. Sci. 24 9 (2003) 493-499
25. 3H]5-hydroxytryptamine release from rat striatal synaptosomes. Neuropharmacology 39 (2000) 290-299
26. Ribeiro E.B., Bettiker R.L., Bogdanov M., and Wurtam R.J. Effects of systemic nicotine on serotonin release in rat brain. Brain Res. 621 (1993) 311-318
27. Salin-Pascual R.J., Rosas M., Jimenez-Genchi A., Rivera-Meza B., and Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J. Clin. Psychiatry 57 (1996) 387-389
28. Schmidt A.W., and Peroutka S.J. 5-Hydroxytriptamine receptor "families". FASEB 3 (1989) 2242-2249
29. Squadrito F., Calapai G., Campo G.M., Zingarelli B., Arcoraci V., Inoculano M., Buemi A.L., Cucinotta D., Saitta A., De Luca G., Gorini A., and Caputi A.P. Indolepyruvic acid, a tryptophan keto analogue, reduces food intake in obese Zucker rats. Neurosci. Res. Commun. 9 (1991) 27-36
30. G-nitro-l-arginine, an inhibitor of brain nitric oxide synthase, in obese Zucker rats. Eur. J. Pharmacol. 230 1 (1993) 125-128
31. Stankov B.M., and Firenzuoli F. 3rd SIFIT congress, Jesi, 2-4 May 1997; modification of the method described in: Kartnig T and Göbel I. J. Chromatogr. 609 1-2 (1992) 423-426
32. 1B receptor antagonists and paroxetine or fluoxetine in the forced swimming test in rats. Pol. J. Pharmacol. 54 (2002) 615-623
33. Teufel-Mayer R., and Gleitz J. Effects of long-term administration of hypericum extracts on the affinity and density of the central serotonergic 5HT1A and 5HT2A receptors. Pharmacopsychiatry 30 Suppl. 2 (1997) 113-116
34. Wevers A., Jeske A., Lobron C., Birtsch C., Heinemann S., Maelicke A., Schroder R., and Schroder H. Cellular distribution of nicotine acetylcholine receptor subunit mRNAs in the human cerebral cortex as revealed by non-isotopic in situ hybridization. Brain Res. Mol. Brain Res. 25 (1994) 122-128
35. Wong M.L., and Licinio J. Research and treatment approaches to depression. Nat. Rev. Neurosci. 2 (2001) 343-351